Corbus Pharmaceuticals Holdings, Inc. develops immune modulators for immuno-oncology and fibrosis diseases, including lenabasum, CRB-601, and CRB-602. They also focus on developing cannabinoid receptor type 1 inverse agonist programs for various diseases. The company has a licensing agreement with Jenrin Discovery, LLC, and was founded in 2009 in Norwood, Massachusetts.